Citadel Advisors
ERNA icon

Citadel Advisors’s Eterna Therapeutics ERNA Stock Holding History

Citadel Advisors’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$216K – 14028
2021
Q3 		$216K Sell
3
-12
-80% -$1.04M ﹤0.01% 11825
2021
Q2 		$2.07M Buy
+15
New +$2.16M ﹤0.01% 6536

Other funds holding ERNA

Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Citadel Advisors's ERNA Position: Q2 2026 in Review

Citadel Advisors increased its Eterna Therapeutics (ERNA) stake by 1,042% in Q2 2026, buying an estimated $97.9K and bringing the position to 15,104 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #12700.

Citadel Advisors first reported a position in ERNA in Q3 2018 and has held it in 14 quarters since. The position peaked at $490K in Q4 2021. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

  • Citadel Advisors held 15,104 shares of Eterna Therapeutics worth $100K as of Q2 2026.
  • Citadel Advisors bought 13,781 Eterna Therapeutics shares in Q2 2026, an estimated $97.9K.
  • Eterna Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12700 holding.
  • Citadel Advisors first reported a position in Eterna Therapeutics in Q3 2018 and has held it in 14 quarters since.
  • Citadel Advisors's Eterna Therapeutics position peaked at $490K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.